Introduction Drug-allergy interaction (DAI) alerts are generated when a known adverse sensitivity-inducing substance is prescribed. A recent study at our institution showed that providers overrode most DAI alerts, including those that warned against potentially life-threatening 'anaphylaxis'. Objective The aim of this study was to determine the rate of anaphylaxis overrides, the reasons for these overrides, whether the overrides were appropriate, and if harm occurred from overrides. Methods All DAI alerts, with a reaction of 'anaphylaxis', were analysed for inpatients and outpatients within our health system between January 2009 and December 2011. Only alerts that were triggered by 'definite' alerts (i.e. same ordered medication as documented allergen) were included. Patient charts were reviewed to assess the appropriateness of overrides and potential harm, according to a predetermined set of criteria.
Background
Adverse drug reactions (ADRs) are responses to medications at normal human doses, which are noxious and unintended [1] . Drug allergies represent one type of ADRs; clinically, & David W. Bates dbates@bwh.harvard.edu both sensitivities and allergies are often reported as allergies by clinicians, however true allergies are immunologicallymediated hypersensitivity reactions that can range from mild reactions (e.g. itching) to severe reactions, such as anaphylaxis [2] . These reactions account for\ 10% of ADRs [3] . A large epidemiologic study of patient-reported allergy within our health system found that 35.5% of our patients had documentation of at least one allergy, with 54.7% of this population only having one allergy documented [4] . Anaphylaxis, which is the sudden onset of a life-threatening systemic or hypersensitivity reaction, has been estimated to have a lifetime risk of 1.6% in the general population [5] . The true incidence of medication-induced anaphylaxis is unknown, with variability based on medications, patient risk factors, and populations [3] . Antibiotics such as penicillin represent a common documented allergen but most lack objective evidence of reactions (i.e. immunologic testing) [5] . To deliver appropriate decision support in electronic health records (EHRs), it is important to accurately determine what the reaction was, to assess whether or not it appeared to be a true allergy, and to assess whether or not anaphylaxis was present [6] . Nearly all EHRs include 'allergy' modules for documentation of a patient's reported and observed reactions to medications, and, in the US, this is required for EHRs to be certified [7] ; however, not all of these EHRs separate anaphylaxis from other types of reactions. A recent study conducted at our institution showed that the majority of reported reactions were commonly entered as 'unknown' [8] .
Given the severity of anaphylaxis, it would be expected that such clinical decision support (CDS) alerts would rarely be overridden; however, data suggest otherwise, with data identifying an override rate of approximately 80% [9] . Some of the reasons for this include poor allergy record stewardship and alert fatigue [8] [9] [10] . In this study, we assessed (1) how many alerts related to anaphylaxis were present and how often they were overridden; (2) the reasons that providers overrode them; (3) the appropriateness of these overrides; and (4) harm that occurred upon administration of an overridden alert.
Methods
Drug-allergy interaction (DAI) alerts with a documented reaction of 'anaphylaxis' in a patient's medical record were included from January 2009 to December 2011 for inpatients at Brigham and Women's Hospital (BWH) and outpatients from primary care practices affiliated with Partners HealthCare, an integrated healthcare delivery system in the greater Boston area that was founded by BWH and Massachusetts General Hospital (MGH), both large academic tertiary care centres. A patient's allergy information is entered into the EHR, which is then stored in a health-system-wide repository, allowing for longitudinal record access [11] . Only drug allergies identified as a 'definite' match between the ordered medication and the documented allergen were included in this analysis. These alerts were chosen given the highly sensitive mapping of medication cross-reactivity that has been identified in the literature [8] . Using a patient with an 'amoxicillin' allergy as an example, an alert with 'amoxicillin' ordered would be included in this study, while an alert with 'ampicillin' ordered would not be included in this study.
When a medication is ordered, it is compared with a patient's reported allergies using a commercial knowledge base (First DataBank, South San Francisco, CA, USA). If there is a potential interaction between this documentation and the ordered medication, a DAI alert fires and is displayed on the provider's computer screen. These alerts are interruptive, requiring a provider to either cancel the order or to override the alert. In this study, allergy entries were entered by either a nurse practitioner, physician, or physician assistant. In the inpatient setting, providers can see the documented reaction and the reason for a previous override of this alert for a patient, and can input a free-text reason for overriding this alert (Fig. 1 ). In the outpatient setting, providers can see the documented reaction and choose to keep the order through one of the following mechanisms: (1) choose 'Patient does not have this allergy, will D/C preexisting allergy'; (2) choose a coded reason for override (i.e. no reasonable alternatives); or (3) input a free-text reason for the override (Fig. 2) . Only one alert was included for each medication order, regardless of setting.
Data included the ordered medication and the documented allergen in the patient's medical record that triggered the DAI alert, and the documented reason for override. The appropriateness of the override was assessed through detailed chart review according to a priori criteria developed by a multidisciplinary group. The criteria covered the evaluation of the documented override reason, evidence of previous tolerance of the medication, and whether the medication was ordered for a desensitization by an allergy specialist. In evaluating the override coded reason 'Physician aware', we evaluated documented notes in the patient record demonstrating that the medical team was actually aware that the patient had a medication ordered, despite a documented reaction of 'anaphylaxis', or if the patient had previously tolerated the medication.
Results
There were a total of 158,023 DAI alerts (inpatient: n = 131,615; outpatient: n = 26,408) during the study period, 2066 of which (1.3% of DAI alerts) [inpatient: n = 1851; outpatient: n = 215] had a reaction of 'anaphylaxis.' These overrides were obtained from 499 inpatient encounters with a median of one alert per encounter (interquartile range [IQR] 1-4), and 140 outpatient visits with a median of one alert per visit (IQR 1-2). The override rates for all alerts were 68.7 and 61.9% in the inpatient and outpatient settings, respectively. Demographics of patients are detailed in Table 1 , and a study flowchart is detailed in Fig. 3 .
After reviewing alert content for non-'definite' matches, a total of 218 (10.5%) alerts remained (inpatient, n = 202, 10.9%; outpatient, n = 16, 7.4%). The largest category of exclusion was that of antimicrobials and cross-sensitivity between the allergen and the ordered medication (n = 795, 43.0%). The group of 'definite' overrides was derived from 107 inpatient encounters with a median of one alert per encounter (IQR 1-2), and 13 outpatient visits with a median of one alert per visit (IQR 1-1). The rate of 'definite' anaphylaxis DAI alert overrides was 46.0% (n = 93) and 68.8% (n = 11) in the inpatient and outpatient settings, respectively. The most common allergens associated with medication actions or overrides are detailed in Tables 2 and 3 for the inpatient and outpatient settings, respectively.
In evaluating the 93 overrides in the inpatient setting, aspirin was the most common allergen (n = 13, 14.0%), with chemotherapy agents and antimicrobials the most common medication classes of allergens overridden (n = 49, 52.7%; and n = 9, 9.7%, respectively). A total of 78 of the 93 overrides were identified to have been appropriate overrides (83.9%). 'Administer per desensitization protocol' was the most common override reason (n = 61, 82.1%). Of the 78 appropriately overridden alerts, 67 resulted in medication administration (85.9%), with a median of one administration (IQR 1-1). Only two of the appropriately overridden alerts resulted in eventual Evaluation of 'Definite' Anaphylaxis Drug Allergy Alertdiscontinuation of the allergen (2.6%), which was not accomplished during the patient's stay. The override reasons for these cases were 'Pt allergic to IV contrast not Readicat [barium sulfate]' (entered instead of Readi-cat in our system) and 'Physician aware'. Of the appropriate overrides that resulted in medication administration, 57 had a documented override reason of 'desensitization' (85.1%), only one of which was not ordered via a desensitization protocol (1.8%). No patient harm was found to have occurred following medication administration of the nondesensitization orders. Of the 15 inappropriately overridden DAI alerts in the inpatient setting, 'Physician aware' was the most common reason for the override (n = 6, 40.0%), with 'Low risk cross sensitivity' being the second most common (n = 3, 20.0%). Twelve of the inappropriately overridden alerts did not pass order verification by the pharmacist either due to pharmacist intervention or from the provider subsequently discontinuing the order after order entry. The remaining three overrides were for prochlorperazine suppositories ordered as needed, which the patient was never administered.
In evaluating the 11 overrides in the outpatient setting, all were identified to be appropriately overridden (100%).
Aspirin was the most commonly overridden allergen (n = 5, 55.5%), followed by morphine (n = 2, 22.2%). The most common reason for an appropriate override was 'Patient does not have this allergy-will D/C pre-existing allergy' (n = 7). In all of these cases, the allergen was removed from the patient's medical record.
Discussion
We assessed how often anaphylaxis was presented as the potential reaction when allergy warnings were displayed, how often warnings were overridden, and what the clinical consequences of these overrides were for the patient. Although 'anaphylaxis' alerts were rare (1.3% of DAI alerts), we found that overrides were common, over 80% of overrides were appropriate, and no overrides induced harm, including inappropriately overridden alerts as no medication administration occurred from these alerts. Many of these warnings occurred in the context of desensitization protocols that usually require additional knowledge and attention by specialists. Overall, these data suggest that while anaphylaxis can be very serious, clinicians in this institution appeared appropriately concerned about it and were making good clinical decisions. Overrides of DAI alerts have been identified as common in previous studies, with rates ranging from 80 to 96% [8] [9] [10] [11] . However, according to our data, anaphylaxis seems to be a rare type of allergic reaction. Override rates for anaphylaxis alerts for any DAI (i.e. not specific to 'definite' matches) were previously found to be 81.9 and 77.0% in the inpatient and outpatient settings, respectively [8] . These findings differ from ours, which were higher in the outpatient setting. On the one hand, it might be expected that override rates of 'anaphylaxis' alerts would be lower in the outpatient setting as patients are less closely monitored, while, on the other hand, the override rate might be higher given the greater familiarity of patients to their primary care providers, whereas inpatient providers would be less likely to be familiar with a patient's past medical history and therefore may be less likely to override alerts, except in the cases of medication desensitization.
In terms of the documented override reason given that only 'definite' alerts were considered, the alerts with an override reason of 'Low risk cross sensitivity' were an interesting finding. This override reason may have resulted from alert fatigue. Since a significant portion of the inpatient and outpatient overrides (73.0% of all overrides) were triggered in the context of desensitization protocols (inpatient: 68.8%; outpatient: 9.1%), suppressing allergy alerts from these order sets should be considered to reduce the alert burden for providers.
In evaluating the appropriateness of these DAI overrides, we found a very high proportion to be appropriately overridden. These results correspond to other studies that found an appropriateness rate of DAI overrides of 96.0 and 70.9% in the inpatient and outpatient settings, respectively [8] . Of greater significance than the appropriateness of the override is whether patients were actually harmed by CDS alert overrides. In a study focused on DAI, 22 potential adverse drug events (ADEs) were found over a 3-month period [10] . A total of 19 were confirmed to be ADEs via a physician panel discussion, of which 10 (52.6%) were identified to be classified as 'significant', with 9 classified as serious ADEs; however, none of these ADEs were identified to have been preventable. In our study, no harm occurred as a result of these overrides, which is of note as there was no difference between appropriately and inappropriately overridden anaphylaxis alerts because no inappropriately overridden alerts resulted in medication administration to the patient. Similar to our study, the most common reason for overriding these DAI alerts in another publication was that the patient had previously tolerated the medication (50.9%) [9] . However, data suggest that a patient's allergy list is updated in only 16.7% of the time, which is particularly striking if 'has previously tolerated' or 'patient does not have this allergy' were entered by providers [10] . The authors suggest that this may be due to reliance on patient self-report, infrequent updating of allergies, or the numerous locations where allergies may be documented in a patient's medical record. Data are expressed as n (%) unless otherwise specified Data are expressed as n (%) unless otherwise specified
Our study has several limitations. This study was conducted within one health system and therefore the results may not be generalizable to other systems or settings. Although this was completed in a legacy, homegrown EHR, we do not expect the findings of this study to differ from what we would find in our current commercial EHR as the same knowledge base is being used. We were not able to validate whether the documented anaphylaxis in these DAI alerts was a true reaction through laboratory or testing information. Our study suggests that documentation of 'anaphylaxis' is not very specific, given that a common override reason was that the patient did not actually have this allergy. In cases in which a provider overrides an alert due to the perception of a false negative (i.e. override of an alert in a patient with actual anaphylaxis), there is a risk of anaphylaxis recurrence in approximately one-third of patients [12] . Recommendations for improved DAI include increased accuracy of allergy documentation, with reconciliation and stewardship of a patient's documented allergic reactions, and the creation of algorithms designed to improve allergy documentation by identifying likely causes of the underlying reaction [6, 13] .
At best, inappropriate drug allergy alerts can waste clinicians' time, therefore it is very important that the information contained in patients' drug allergy lists and the clinical evidence on drug cross-reactivity in the decision support systems is always up to date. All EHRs should collect information on allergic reactions, with anaphylaxis being a particularly important reaction. It might be helpful in the future to ask providers why they believe the reaction was anaphylaxis to enable better downstream decision making. Additionally, removal of these alerts may be beneficial when a desensitization protocol is ordered.
Conclusion
We found a high rate of overrides of warnings against definite anaphylaxis, but a high proportion of these overrides were judged to be appropriate in both inpatient and outpatient settings. Desensitization protocols should be modified to bypass these warnings. Improved patient allergy reconciliation may also be beneficial in reducing the alert burden associated with these potentially critical alerts.
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